Skip to contentSkip to Braille Studio

Library / Laws / 116th / hr / H.R. 4632 / Introduced in House

H.R. 4632 — Introduced in House

364 words · about 2 min to read

Download .txt All versions Braille ⠃⠗⠋ Print Cite

I 116th CONGRESS 1st Session H. R. 4632 IN THE HOUSE OF REPRESENTATIVES October 11, 2019Mr. Kind (for himself, Ms. Davids of Kansas, and Mr. Butterfield) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to disseminate to part D subsidy eligible individuals information comparing the premiums under LIS benchmark plans for such individuals. 1. Short title This Act may be cited as the Better Transparency in Information for Medicare Beneficiaries Act of 2019. 2. Dissemination to Medicare part D subsidy eligible individuals of information comparing premiums of certain prescription drug plans Section 1860D–1(c)(3) of the Social Security Act (42 U.S.C. 1395w–101(c)(3)) is amended by adding at the end the following new subparagraph: (C) Information on premiums for subsidy eligible individuals (i) In general For plan year 2022 and each subsequent plan year, the Secretary shall disseminate to each subsidy eligible individual (as defined in section 1860D–14(a)(3)) information under this paragraph comparing premiums that would apply to such individual for prescription drug coverage under LIS benchmark plans, including, in the case of an individual enrolled in a prescription drug plan under this part, information that compares the premium that would apply if such individual were to remain enrolled in such plan to premiums that would apply if the individual were to enroll in other LIS benchmark plans. (ii) LIS benchmark plan For purposes of clause (i), the term LIS benchmark plan means, with respect to an individual, a prescription drug plan under this part that is offered in the region in which the individual resides and— (I) that provides for a premium that is not more than the low-income benchmark premium amount (as defined in section 1860D–14(b)(2)) for such region; or (II) with respect to which the premium would be waived as de minimis pursuant to section 1860D–14(a)(5) for such individual. .